1 – 5 of 5
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2023
-
Mark
The 2022 Updated European Association of Urology Guidelines on the Use of Adjuvant Immune Checkpoint Inhibitor Therapy for Renal Cell Carcinoma
(
- Contribution to journal › Article
- 2022
-
Mark
2021 Updated European Association of Urology Guidelines on the Use of Adjuvant Pembrolizumab for Renal Cell Carcinoma
(
- Contribution to journal › Article
- 2021
-
Mark
The Impact of Histological Subtype on the Incidence, Timing, and Patterns of Recurrence in Patients with Renal Cell Carcinoma After Surgery-Results from RECUR Consortium
(
- Contribution to journal › Article
-
Mark
Updated European Association of Urology Guidelines on Renal Cell Carcinoma : Nivolumab plus Cabozantinib Joins Immune Checkpoint Inhibition Combination Therapies for Treatment-naïve Metastatic Clear-Cell Renal Cell Carcinoma
(
- Contribution to journal › Article
- 2020
-
Mark
Features of increased malignancy in eosinophilic clear cell renal cell carcinoma
(
- Contribution to journal › Article